Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1374699rdf:typepubmed:Citationlld:pubmed
pubmed-article:1374699lifeskim:mentionsumls-concept:C0042523lld:lifeskim
pubmed-article:1374699lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:1374699lifeskim:mentionsumls-concept:C0279023lld:lifeskim
pubmed-article:1374699pubmed:issue5lld:pubmed
pubmed-article:1374699pubmed:dateCreated1992-6-12lld:pubmed
pubmed-article:1374699pubmed:abstractTextTo assess the effects of verapamil on postextrasystolic potentiation (PESP), contrast left ventriculography was performed in ten healthy anesthetized dogs before and after the intravenous administration of verapamil, 0.1 mg/kg. During the contrast ventriculography, a single atrial premature stimulus was introduced. Ejection fractions of a control beat and postpremature beat were measured before and after verapamil. Before verapamil, the mean ejection fractions of the control beat and the postpremature beat were 60 +/- 10 percent and 67 +/- 10 percent, respectively (p less than 0.05). Following the administration of verapamil, the mean ejection fraction of the control beat decreased from 60 +/- 10 percent to 55 +/- 11 percent (p less than 0.05). However, the mean ejection fraction of the postpremature beats increased when compared with the control beats following intravenous verapamil (65 +/- 8 percent and 55 +/- 11 percent, respectively; p less than 0.05). These results suggest that PESP is not inhibited by the administration of intravenous verapamil.lld:pubmed
pubmed-article:1374699pubmed:languageenglld:pubmed
pubmed-article:1374699pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1374699pubmed:citationSubsetAIMlld:pubmed
pubmed-article:1374699pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1374699pubmed:statusMEDLINElld:pubmed
pubmed-article:1374699pubmed:monthMaylld:pubmed
pubmed-article:1374699pubmed:issn0012-3692lld:pubmed
pubmed-article:1374699pubmed:authorpubmed-author:RysavyJJlld:pubmed
pubmed-article:1374699pubmed:authorpubmed-author:MoossA NANlld:pubmed
pubmed-article:1374699pubmed:authorpubmed-author:HillemanD EDElld:pubmed
pubmed-article:1374699pubmed:authorpubmed-author:SketchM HMHSrlld:pubmed
pubmed-article:1374699pubmed:issnTypePrintlld:pubmed
pubmed-article:1374699pubmed:volume101lld:pubmed
pubmed-article:1374699pubmed:ownerNLMlld:pubmed
pubmed-article:1374699pubmed:authorsCompleteYlld:pubmed
pubmed-article:1374699pubmed:pagination1438-41lld:pubmed
pubmed-article:1374699pubmed:dateRevised2003-11-14lld:pubmed
pubmed-article:1374699pubmed:meshHeadingpubmed-meshheading:1374699-...lld:pubmed
pubmed-article:1374699pubmed:meshHeadingpubmed-meshheading:1374699-...lld:pubmed
pubmed-article:1374699pubmed:meshHeadingpubmed-meshheading:1374699-...lld:pubmed
pubmed-article:1374699pubmed:meshHeadingpubmed-meshheading:1374699-...lld:pubmed
pubmed-article:1374699pubmed:meshHeadingpubmed-meshheading:1374699-...lld:pubmed
pubmed-article:1374699pubmed:meshHeadingpubmed-meshheading:1374699-...lld:pubmed
pubmed-article:1374699pubmed:meshHeadingpubmed-meshheading:1374699-...lld:pubmed
pubmed-article:1374699pubmed:meshHeadingpubmed-meshheading:1374699-...lld:pubmed
pubmed-article:1374699pubmed:year1992lld:pubmed
pubmed-article:1374699pubmed:articleTitleEffects of verapamil on postextrasystolic potentiation.lld:pubmed
pubmed-article:1374699pubmed:affiliationDivision of Cardiology, Creighton University School of Medicine, Omaha.lld:pubmed
pubmed-article:1374699pubmed:publicationTypeJournal Articlelld:pubmed